Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-06-03 00:00:00 ET · period of report 2024-05-30 · accession 0000875320-24-000166 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-06-03 | 2024-05-30+ | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $441.99 | -4,600 | 51.3K | -8% | -$2.03M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-30 | S | D | 2,350 | $439.11 | 53,523 | D | — | — | |
| 2 | Common | Common Stock | 2024-05-31 | S | D | 2,250 | $445.00 | 51,273 | D | — | — |